A phase II study of capecitabine plus oxaliplatin (XELOX): a new first-line option in metastatic colorectal cancer.
Makatsoris T, Kalofonos HP, Aravantinos G, Papadimitriou C, Kastritis E, Rigatos SK, Xiros N, Petsas T, Economopoulos T, Sakadamis AK, Fountzilas G; Hellenic Cooperative Oncology Group.
Makatsoris T, et al. Among authors: fountzilas g.
Int J Gastrointest Cancer. 2005;35(2):103-9. doi: 10.1385/ijgc:35:2:103.
Int J Gastrointest Cancer. 2005.
PMID: 15879624
Clinical Trial.